Multiple myeloma (MM) is a plasma cell malignancy that is still considered to be incurable in
most cases. A dominant mutation cluster has been identified in RAS/RAF genes …

In multiple myeloma the mutational profile is mainly represented by translocations involving
chromosome 14 and by single nucleotide mutations, frequently involving genes implicated …

Multiple myeloma (MM) is a clinically and genetically heterogeneous plasma cell (PC)
malignancy. Whole-exome sequencing has identified therapeutically targetable mutations …

A major driver of multiple myeloma (MM) is thought to be aberrant signaling, yet no kinase
inhibitors have proven successful in the clinic. Here, we employed an integrated, systems …

Multiple Myeloma (MM) is a malignant plasma cell disorder with an unmet medical need, in
particular for relapsed and refractory patients. Molecules within deregulated signaling …

Purpose: Copy-number changes and translocations have been studied extensively in many
datasets with long-term follow-up. The impact of mutations remains debated given the short …

We have recently shown that approximately half of primary multiple myeloma (MM) samples
display constitutive Akt activity, which disposes them for sensitivity to Akt inhibition. The Akt …

Abstract The Ras/Raf/MEK/extracellular signal regulated kinase (ERK)(Ras/mitogen-
activated protein kinases (MAPK)) signal transduction pathway is a crucial mediator of many …

Multiple myeloma (MM) is a largely incurable plasma cell malignancy with a poorly
understood and heterogeneous clinical course. To identify potential, functionally relevant …

Mutations of members of the ras family are among the most common oncogene mutations
found in multiple myeloma (MM). We have examined the mutational status of the N-and K …